Sanofi (NASDAQ:SNY) Shares Sold by D.A. Davidson & CO.

D.A. Davidson & CO. lowered its position in shares of Sanofi (NASDAQ:SNY) by 2.9% in the third quarter, HoldingsChannel.com reports. The fund owned 10,823 shares of the company’s stock after selling 327 shares during the quarter. D.A. Davidson & CO.’s holdings in Sanofi were worth $624,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in SNY. Manning & Napier Advisors LLC acquired a new stake in shares of Sanofi during the second quarter worth about $13,725,000. GFS Advisors LLC lifted its stake in Sanofi by 1,017.9% during the 3rd quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock valued at $738,000 after acquiring an additional 11,655 shares during the period. Legacy Capital Wealth Partners LLC boosted its holdings in shares of Sanofi by 114.2% in the 3rd quarter. Legacy Capital Wealth Partners LLC now owns 24,274 shares of the company’s stock valued at $1,399,000 after acquiring an additional 12,942 shares during the last quarter. Envestnet Portfolio Solutions Inc. increased its stake in shares of Sanofi by 15.2% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 116,917 shares of the company’s stock worth $5,673,000 after acquiring an additional 15,439 shares during the period. Finally, Icon Wealth Advisors LLC raised its holdings in shares of Sanofi by 7,954.4% during the third quarter. Icon Wealth Advisors LLC now owns 292,779 shares of the company’s stock worth $16,873,000 after purchasing an additional 289,144 shares during the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on SNY. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Citigroup raised Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Stock Down 1.1 %

SNY opened at $47.96 on Tuesday. The company has a fifty day moving average of $52.80 and a two-hundred day moving average of $52.15. The stock has a market capitalization of $121.71 billion, a price-to-earnings ratio of 24.74, a PEG ratio of 1.23 and a beta of 0.61. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $0.22 by $1.35. The firm had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. Sanofi’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.55 EPS. On average, research analysts expect that Sanofi will post 4.28 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.